The Crescentino Question: Versalis, Proesa® and the Grey Zone of Italy’s R&D Tax Credits
When Eni subsidiary Versalis acquired the bioeconomy assets of Mossi & Ghisolfi in late 2018, the deal was presented as a strategic rescue of one of Europe’s most ambitious advanced biofuel projects.
At the center of the acquisition was the Crescentino cellulosic ethanol plant in northern Italy and the proprietary Proesa® technology platform — once hailed as a breakthrough in second-generation bioethanol production.
But years later, the acquisition also raises a less explored question: how should post-acquisition research spending linked to acquired industrial technology be treated under Italy’s generous R&D tax-credit regime?
The 2018 Acquisition
In November 2018, Versalis completed the acquisition of the “Bio” business units of the financially troubled Mossi & Ghisolfi group for approximately €75 million, together with the assumption of a financial lease estimated at around €19 million.
The transaction included:
- the Crescentino bioethanol plant,
- the Proesa® technology,
- intellectual property rights,
- engineering capabilities,
- and related R&D activities.
The acquisition represented a major strategic move for Versalis, which had been seeking to expand its position in renewable chemistry and bio-based industrial technologies.
Crescentino itself held symbolic importance within Europe’s bioeconomy sector. Opened in 2013, the plant was among the world’s first commercial-scale facilities designed to produce ethanol from agricultural residues rather than food crops. Yet despite its technological promise, the project struggled commercially and became entangled in the wider financial collapse of Mossi & Ghisolfi.
Italy’s R&D Tax Credit Framework
Italy has long operated an extensive tax incentive regime designed to stimulate industrial research and innovation. The rules, shaped by successive legislative reforms and aligned with OECD Frascati Manual principles, allow companies to claim tax credits on qualifying research and development expenditure.
However, the framework draws an important distinction between:
- the acquisition of externally developed technology,
- and internally conducted experimental research activity.
Under OECD principles, the mere purchase of patents, know-how, or industrial technologies generally does not qualify as R&D expenditure. By contrast, subsequent experimental development, process optimization, pilot testing, and internally conducted engineering research may qualify if they involve genuine scientific or technological uncertainty.
That distinction has become increasingly important as Italian tax authorities have intensified scrutiny of corporate R&D credit claims across several industrial sectors, including chemicals and pharmaceuticals.
The Proesa® Complexity
Following the acquisition, Versalis continued reporting annual R&D expenditure in the range of roughly €38–46 million. Part of that spending was associated with renewable chemistry and the continued industrial development of the Crescentino platform.
This creates a technically complex accounting and tax-policy question.
Because Proesa® was acquired technology rather than internally invented by Versalis, any attempt to classify acquisition-related costs themselves as qualifying R&D expenditure would likely face scrutiny under Italian tax rules. At the same time, subsequent engineering improvements, process optimization, and new industrial applications linked to the technology could potentially qualify if they constituted genuine experimental development activities.
The challenge lies in determining where operational implementation ends and new research begins.
That boundary is often difficult to define in industrial biotechnology, where commercial-scale deployment frequently requires years of additional engineering refinement after an initial technology acquisition.
A Broader Issue Across Italian Industry
The Crescentino case illustrates a wider issue within Italy’s innovation-incentive system.
In recent years, the Agenzia delle Entrate and financial authorities have challenged numerous R&D tax-credit claims involving disputes over whether expenditures represented:
- true experimental research,
- ordinary industrial engineering,
- or the adaptation of previously acquired technologies.
The distinction has become particularly contentious in capital-intensive sectors such as chemicals, pharmaceuticals, advanced materials, and industrial biotechnology, where companies often acquire external intellectual property before investing heavily in commercialization and scale-up activities.
For policymakers, the issue reflects a broader tension at the heart of industrial innovation policy: encouraging companies to invest in advanced technologies while preventing the reclassification of acquisition and implementation costs as research expenditure.
The Industrial Outcome
Despite the difficulties surrounding the original Mossi & Ghisolfi venture, Versalis has continued investing in the Crescentino site and restarted bioethanol production in subsequent years as part of Eni’s wider transition strategy toward bio-based and circular industrial activities.
Whether the long-term economics of second-generation bioethanol ultimately justify those investments remains debated within the industry. Yet the Crescentino project continues to stand as one of Europe’s most significant — and controversial — experiments in industrial-scale advanced biofuels.
At the same time, it highlights how the financial, accounting, and regulatory treatment of industrial innovation can become almost as complex as the technologies themselves.
More
I believe that the Italian oil company ENI, its plastics-related subsidiary Novamont, and possibly individuals connected in some way to the European Commission may be involved—directly or indirectly—in initiating legal actions that I perceive as SLAPPs against me. I cannot independently verify the full extent or coordination of these actions, but from my perspective they appear to be part of a broader pattern of legal pressure.
Disclaimer
This article is based on publicly available information, including corporate reports, press releases, and applicable legal and policy frameworks concerning research and development tax incentives in Italy.
It is intended for informational and analytical purposes only and does not assert or imply any unlawful conduct by any company or individual mentioned, including Eni or Versalis.
The discussion of R&D tax credit eligibility and classification reflects general interpretation of applicable rules and does not constitute legal, tax, or financial advice.
Where questions of interpretation arise, they relate to structural and policy-level issues within innovation incentive systems rather than allegations regarding specific corporate behaviour.
Readers should be aware that assessments of R&D eligibility can vary depending on technical, legal, and administrative interpretation, and may be subject to revision by competent authorities.